Rezdiffra Q2 2026 sales reach $364.3 million, up 71% YoY; trailing-12-month revenue exceeds $1.3 billion

Madrigal Pharmaceuticals/Rezdiffra

Madrigal reported Q2 2026 Rezdiffra sales of $364.3 million, representing 71% year-over-year growth from $212.8 million in Q2 2025. Trailing-12-month revenue exceeded $1.3 billion, reflecting rapid adoption and market expansion for the first approved MASH therapy. Growth drivers included continued U.S. market penetration and launch in European markets including Germany.